Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).
Once metastatic bladder cancer has progressed to first-line treatment, the number of therapeutic options is scarce. Among chemotherapeutic agents showing activity in phase II trials, including taxanes, vinflunine (VFL) is the only one shown to increase overall survival in a phase III trial. In addition to its efficacy, VFL is safe in special population groups. Despite this, the prognosis for these patients remains poor, and more effective therapies need to be developed. Agents acting on new therapeutic targets as well as biomarkers to aid matching patients to specific treatments are currently under evaluation. In this regard, immunotherapy is showing promising results. In this article, a critical review of current treatments and future prospects is made, and therapy recommendations are made based on existing scientific evidence.
Department of Oncology, Santiago University Hospital, Santiago, Spain.
Jorge
J
García
Department of Oncology, POVISA Hospital, Vigo, Spain.
Lucia
L
Santomé
Department of Oncology, Santiago University Hospital, Santiago, Spain.
Urbano
U
Anido
Department of Oncology, Ourense University Hospital, Ourense, Spain.
Ovidio
O
Fernández-Calvo
Department of Oncology, Ferrol University Hospital, Ferrol, Spain.
Javier
J
Afonso-Afonso
Department of Oncology, Álvaro Cunqueiro Hospital, Vigo, Spain.
Martín
M
Lázaro
Department of Oncology, Galicia Oncology Center, A Coruña, Spain.
Ana
A
Medina
Department of Oncology, Lucus Augusti University Hospital, Lugo, Spain. sergio.vazquez.estevez@sergas.es.
Sergio
S
Vázquez Estévez
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D058990:Molecular Targeted Therapy; D017410:Practice Guidelines as Topic / Q000592:standards*; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000556:secondary
D000970:Antineoplastic Agents
Bladder cancer; Prognostic factors; Second-line treatment; Vinflunine